Literature DB >> 11422199

Differential requirement for interferon-gamma to restrict the growth of or eliminate some recently identified species of nontuberculous mycobacteria in vivo.

S Ehlers1, E Richter.   

Abstract

In recent years, a number of newly identified species of the genus Mycobacterium (M.) have been isolated from tissues of both immunocompetent and immunocompromised patients, e.g. M. celatum, M. intermedium, M. interjectum, M. bohemicum, M. conspicuum, M. confluentis, M. heidelbergense, M. lentiflavum, and M. branderi. Little is known about their in vivo virulence characteristics and the host factors predisposing to infection with these strains. In an effort to elucidate the pathogenesis of these nontuberculous mycobacterial species, BALB/c and syngeneic IFNgamma-deficient (GKO) mice were intravenously infected with 106 colony forming units of each of these species, and bacterial growth in infected organs and the development of splenomegaly and granulomatous liver lesions were examined for a period of 3 months. Based on their in vivo virulence, mycobacterial strains could be divided into three major groups: (i) Most species examined either grew progressively or persisted at plateau levels in the livers and spleens of immunocompetent mice, and their growth was increased in GKO mice. (ii) M. heidelbergense, M. intermedium and another species not officially accorded separate taxonomical status were eliminated in BALB/c mice, but persisted in GKO mice. (iii) M. confluentis, M. lentiflavum and another novel species were eradicated even in the absence of IFNgamma. Nontuberculous mycobacterial species differed widely in their capacity to induce splenomegaly and lymphadenopathy in GKO mice. In conclusion, IFNgamma is a crucial determinant of infection outcome with most, but not all opportunistic mycobacterial species.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422199      PMCID: PMC1906046          DOI: 10.1046/j.1365-2249.2001.01509.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  57 in total

1.  Mycobacterium malmoense infections in immunocompetent patients.

Authors:  R Enzensberger; K P Hunfeld; M Krause; S Rüsch-Gerdes; V Brade; B Böddinghaus
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-08       Impact factor: 3.267

Review 2.  Mycobacterial diseases other than tuberculosis.

Authors:  E Wolinsky
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  Phenotypic and molecular characterization of three clinical isolates of Mycobacterium interjectum.

Authors:  R Lumb; A Goodwin; R Ratcliff; R Stapledon; A Holland; I Bastian
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

4.  Mycobacterium intermedium sp. nov.

Authors:  A Meier; P Kirschner; K H Schröder; J Wolters; R M Kroppenstedt; E C Böttger
Journal:  Int J Syst Bacteriol       Date:  1993-04

Review 5.  Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review.

Authors:  M Zaugg; M Salfinger; M Opravil; R Lüthy
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

Review 6.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  Mycobacterium interjectum, a new species isolated from a patient with chronic lymphadenitis.

Authors:  B Springer; P Kirschner; G Rost-Meyer; K H Schröder; R M Kroppenstedt; E C Böttger
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

8.  Mycobacterium confluentis sp. nov.

Authors:  P Kirschner; A Teske; K H Schröder; R M Kroppenstedt; J Wolters; E C Böttger
Journal:  Int J Syst Bacteriol       Date:  1992-04

9.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  6 in total

1.  Pulmonary Mycobacterium intermedium disease in an elderly man with healed pulmonary tuberculosis.

Authors:  Akihide Ito; Fujiya Kishi; Nariyoshi Saito; Yuko Kazumi; Satoshi Mitarai
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

2.  Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice.

Authors:  Martin Rottman; Emilie Catherinot; Patrick Hochedez; Jean-François Emile; Jean-Laurent Casanova; Jean-Louis Gaillard; Claire Soudais
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

Review 3.  Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s.

Authors:  Enrico Tortoli
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

4.  Contribution of NK, NK T, gamma delta T, and alpha beta T cells to the gamma interferon response required for liver protection against Trypanosoma cruzi.

Authors:  Luiz Roberto Sardinha; Rosa Maria Elias; Tainá Mosca; Karina R B Bastos; Cláudio R F Marinho; Maria Regina D'Império Lima; José M Alvarez
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

5.  IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts.

Authors:  Martin Rottman; Claire Soudais; Guillaume Vogt; Laurent Renia; Jean-François Emile; Hélène Decaluwe; Jean-Louis Gaillard; Jean-Laurent Casanova
Journal:  PLoS Med       Date:  2008-01-29       Impact factor: 11.069

6.  Mycobacterium interjectum Lung Infection.

Authors:  M C Mirant-Borde; S Alvarez; M M Johnson
Journal:  Case Rep Pulmonol       Date:  2013-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.